What Kuria Therapeutics does

Kuria Therapeutics, Inc. is a preclinical-stage pharmaceutical company founded in 2022 and headquartered in Little Rock, Arkansas, developing novel small-molecule NRF2 activators for ophthalmic and dermal diseases. The company's lead asset is KTX-1161, a topical ophthalmic solution formulation of SCO-116, a macrocyclic compound that selectively inhibits the NRF2-KEAP1 protein-protein interaction through non-covalent binding — a mechanism that differentiates SCO-116 from covalent-binding NRF2 activators and is expected to support a favorable safety profile. The core scientific thesis is that activation of the NRF2 pathway, the master regulator of the cellular antioxidant response, can address the underlying mitochondrial dysfunction and oxidative stress that drive corneal endothelial diseases (Fuchs' dystrophy, post-cataract surgery cell loss) and retinal diseases (dry AMD). SCO-116 was discovered by SCOHIA PHARMA, a Japanese biotech, and is exclusively licensed to Kuria worldwide for topical ophthalmic and dermal applications under a June 2022 agreement that includes up to $67M in potential milestones plus tiered royalties to SCOHIA. The company plans to pursue Phase 2 clinical proof-of-concept studies directly in Fuchs' dystrophy and cataract surgery patients, with a stated exit orientation toward out-licensing or acquisition rather than building commercial infrastructure.

Kuria's primary revenue model is licensing and milestone payments tied to future clinical and commercial success of SCO-116/KTX-1161, not direct product sales. The company is funded by an initial seed round (September 2022), a non-dilutive NIH/NEI SBIR Fast Track Phase I/II grant of up to $2.3M awarded September 2025, and matching funds from the Arkansas Economic Development Commission. Go-to-market motion is event-driven and community-led: leadership actively presents at ARVO Annual Meetings (2024, 2025), the J.P. Morgan Healthcare Conference, Ophthalmology Futures Forums, InvestMidwest Venture Forum, Venture Connect, Texas Life Science Forum, and Southwest Venture Forum to engage key opinion leaders, investors, and prospective partners. The customer base is not commercial in the conventional sense — Kuria's near-term "customers" are clinicians, investigators, and patient advocacy groups who generate demand and clinical evidence, while the economic acquirers will be larger pharmaceutical partners or acquirers post-clinical milestones. The IP foundation rests on US Patent 11,518,763 (composition of matter, issued January 2023), solely owned by SCOHIA PHARMA but exclusively licensed to Kuria for the licensed fields. The leadership team of five executives — CEO Keith Ward, PhD (ex-Reata EVP & CDO, ex-Bausch & Lomb Global VP Pharmaceutical R&D); COO Misty Stevens, PhD, MBA; CDO Dave Flory, MBA (ex-Reata, ex-Unicycive); CMO W. Brooks Gentry, MD (29-year UAMS professor); and CTO Ralph Henry, PhD — brings concentrated NRF2 and ophthalmology development experience to a 1-10 person organization.

Name

Kuria Therapeutics

Legal name

Kuria Therapeutics, Inc.

Website

https://kuriatx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Kuria Therapeutics is a preclinical-stage pharmaceutical company developing novel small-molecule NRF2 activators (lead: KTX-1161, a topical eye drop) for corneal endothelial diseases including Fuchs' dystrophy and for retinal diseases like dry AMD. The company is privately held, based in Little Rock, Arkansas, and out-licensed from SCOHIA PHARMA.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Ophthalmology Pharmaceuticals (HLAIAAAL), Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Ophthalmic pharmaceuticals
• NRF2 activators
• Corneal endothelial disease
• Topical ophthalmic drugs
• Preclinical biotech

Headquarters

HQ city

Little Rock

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Licensing and Milestone Payments: Under the licensing agreement with SCOHIA PHARMA, Kuria received exclusive worldwide rights to develop, manufacture, and commercialize SCO-116 for ophthalmic and dermal diseases. SCOHIA PHARMA receives an upfront payment and is eligible for up to USD 67 million in potential regulatory, development, and commercial milestone payments, plus tiered royalties as a percentage of net sales. This represents the company's primary revenue model: out-licensing or being acquired by a larger pharma company upon clinical milestones.
2. Non-Dilutive Grant Funding: Kuria has secured non-dilutive funding through NIH SBIR grants (up to $2.3M Fast Track Phase I/II from NEI) and matching funds from the Arkansas Economic Development Commission. These grants fund preclinical and IND-enabling development activities without diluting equity.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Core offering

Kuria Therapeutics develops a pipeline of topical ophthalmic drug candidates based on novel small-molecule NRF2 activators (lead compound SCO-116, formulated as KTX-1161 eye drops). The company targets corneal endothelial diseases such as Fuchs' dystrophy and cataract surgery-induced cell loss, with extension into retinal diseases including dry age-related macular degeneration and dermal conditions such as radiation dermatitis. Products are intended to be developed through clinical proof-of-concept and then out-licensed to larger pharmaceutical partners for commercialization.

Product overview

Kuria Therapeutics is a pharmaceutical company developing a platform of novel NRF2 activators for ophthalmic and dermal diseases. The core product is KTX-1161, a topical ophthalmic formulation of the novel small-molecule Nrf2 activator SCO-116. The company's pipeline includes treatments for corneal endothelial diseases (Fuchs' dystrophy, cataract surgery protection) and retinal diseases (dry age-related macular degeneration). The company operates under exclusive worldwide licensing from SCOHIA PHARMA for topical ophthalmic and dermal applications of SCO-116.

Differentiator

Problem solved

Functional benefit

Products and services

• KTX-1161 Topical ophthalmic solution formulation of the novel small-molecule NRF2 activator SCO-116, being developed as a first-in-class disease-modifying therapy for corneal endothelial diseases including Fuchs' endothelial corneal dystrophy and for prevention of corneal endothelial cell loss associated with cataract surgery. Designed for prescription use by ophthalmologists and their patients with no approved pharmacological alternative.

Quantifiable outcome

• Preclinical proof-of-concept demonstrated: SCO-116 improved mitochondrial function in human fibroblasts in vitro, protected human retinal pigment epithelial cells from A2E/blue light insult in vitro, and preserved visual function and retinal structure in sodium iodate-induced geographic atrophy in rats in vivo.
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• SCOHIA PHARMA, Inc.coreTechnology or Integration · 27 June 2022Kuria Therapeutics and SCOHIA PHARMA entered into a strategic licensing agreement under which Kuria received exclusive worldwide rights to develop, manufacture, and commercialize locally delivered formulations of SCO-116 (novel NRF2 activator) for ophthalmic and dermal diseases (designated KTX-1161 for the topical ophthalmic product). SCOHIA PHARMA receives an upfront payment plus up to $67M in potential regulatory, development, and commercial milestones, plus tiered royalties on net sales. SCOHIA retains worldwide rights for SCO-116 for systemic formulations and indications other than eye and skin diseases. A Joint Steering Committee with representatives from both companies provides oversight.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Apellis Pharmaceuticals: Develops targeted therapies for retinal diseases including geographic atrophy (the dry AMD indication Kuria also targets). A relevant competitor in the retinal portion of Kuria's pipeline.
• Iveric Bio (Astellas): Developed Izervay for geographic atrophy secondary to dry AMD, acquired by Astellas in 2023. Most relevant direct competitor in the dry AMD / geographic atrophy space.
• Annexon, Inc. Clinical-stage biotech developing therapeutics for retinal and ophthalmic inflammatory diseases with novel mechanisms. Comparable emerging biotech profile focused on ophthalmology indications.

Direct peers

• Outlook Therapeutics: Specialty ophthalmology biotech developing therapeutics for retinal diseases. Comparable small-cap, single-platform ophthalmology biotech profile.
• Ocuphire Pharma: Late clinical-stage ophthalmology specialty pharma developing therapeutics for front- and back-of-eye indications. Comparable size, therapeutic focus, and clinical-stage profile to Kuria.
• Ocular Therapeutix: Specialty ophthalmology company developing novel drug-delivery formulations for front- and back-of-eye diseases. Comparable in applying innovative delivery (hydrogel inserts / topical) to ophthalmic indications.
• Nicox SA: European ophthalmology specialty company developing small-molecule therapeutics, including novel mechanisms targeting oxidative stress. Comparable specialty-pharma model and therapeutic focus.
• Aldeyra Therapeutics: Clinical-stage specialty ophthalmology pharma developing novel small-molecule therapies for dry eye disease and retinal disorders. Direct comparable in size, stage, and therapeutic-area focus to Kuria.

Broad incumbents

• Bausch + Lomb: Global ophthalmology pharma and device company with broad portfolio across corneal, cataract, and retinal diseases. Source of Kuria's CEO's prior R&D leadership and a likely future commercial partner or acquirer.

Others

• Reata Pharmaceuticals: Developed and won FDA approval for omaveloxolone (Skyclarys), the first approved NRF2 activator. Closely comparable scientifically (NRF2 mechanism) and the source of much of Kuria's leadership team.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kuria-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kuria Therapeutics